Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575799 | 0.89 | PADI4 (0.40) | MAPK14MAPK13MAPK12MAPK11GSK3A | |
| SCHEMBL8324311 | 0.77 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11KIT | |
| SCHEMBL20685590 | 0.68 | ACHE (0.54) | JAK2MAPK1 | |
| SCHEMBL18952058 | 0.66 | CCNB2 (0.54) | KITGSK3AGSK3BCDK5CCNB2 | |
| SCHEMBL31047685 | 0.65 | SERPINE1 (0.69) | MAPK14 | |
| SCHEMBL28297791 | 0.65 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11GSK3A | |
| SCHEMBL17105717 | 0.64 | MAPT (0.50) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL31447389 | 0.62 | CCNB2 (0.50) | KITGSK3AGSK3BCDK5CCNB2 | |
| SCHEMBL27158496 | 0.62 | ALDH1A1 (0.41) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL14678434 | 0.62 | AXL (0.47) | KITGSK3AGSK3BCDK5CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| CN-109748915-B | Inhibitors of influenza virus replication and methods of use and uses thereof | 广东东阳光药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-24 | — | — | US | disclosed |
| US-10717732-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-06 | — | — | US | disclosed |
| EP-3362451-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017097234-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | MAPK14 1771/4885MAPK13 2965/4885MAPK12 2595/4885 |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | MAPK14 1771/4885MAPK13 2965/4885MAPK12 2595/4885 |
| US-10717732-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | MAPK14 1771/4885MAPK13 2965/4885MAPK12 2595/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | MAPK14 1771/4885MAPK13 2965/4885MAPK12 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.